Skip to content
Study details
Enrolling now

Viral Infection in Asthma (VIA) Trial

University of Virginia
NCT IDNCT04380038ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

60

Study length

about 4.7 years

Ages

18–40

Locations

1 site in VA

What this study is about

Researchers are testing if a treatment called dupilumab helps prevent asthma symptoms after being exposed to the common cold virus. Dupilumab is an injectable drug that blocks inflammation in the lungs. The trial will involve adults and track asthma symptoms using lung function tests, questionnaires, and other methods.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Dupilumab Injectable Product

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

injection

Endpoints

Secondary: Change in symptoms post-rhinovirus inoculation

Body systems

Respiratory